Abstract:1. CCNB1IP1 was overexpressed in MYCN‐amplified NB and was associated with poor prognosis. 2. CCNB1IP1 facilitated MYCN‐driven proliferation and tumourigenesis of NB cells. 3. MYCN directly activated CCNB1IP1 transcription, which in turn stabilized MYCN by competing with FBXW7 for MYCN binding in a C‐terminal domain‐dependent manner. Background MYCN amplification as a common genetic alteration that correlates with a poor prognosis for neuroblastoma (NB) patients. However, given the challenge of directly targeting MYCN, indirect strategies to modulate MYCN by interfering with its cofactors are attractive in NB treatment. Although cyclin B1 interacting protein 1 (CCNB1IP1) has been found to be upregulated in MYCN‐driven mouse NB tissues, its regulation with MYCN and collaboration in driving the biological behaviour of NB remains unknown. Methods To evaluate the expression and clinical significance of CCNB1IP1 in NB patients, public datasets, clinical NB samples and cell lines were explored. MTT, EdU incorporation, colony and tumour sphere formation assays, and a mouse xenograft tumour model were utilized to examine the biological function of CCNB1IP1. The reciprocal manipulation of CCNB1IP1 and MYCN and the underlying mechanisms involved were investigated by gain‐ and loss‐of‐function approaches, dual‐luciferase assay, chromatin immunoprecipitation (CHIP) and co‐immunoprecipitation (Co‐IP) experiments. Results CCNB1IP1 was upregulated in MYCN‐amplified (MYCN‐AM) NB cell lines and patients‐derived tumour tissues, which was associated with poor prognosis. Phenotypic studies revealed that CCNB1IP1 facilitated the proliferation and tumourigenicity of NB cells in cooperation with MYCN in vitro and in vivo. Mechanistically, MYCN directly mediates the transcription of CCNB1IP1, which in turn attenuated the ubiquitination and degradation of MYCN protein, thus enhancing CCNB1IP1‐MYCN cooperativity. Moreover, CCNB1IP1 competed with F box/WD‐40 domain protein 7 (FBXW7) for MYCN binding and enabled MYCN‐mediated tumourigenesis in a C‐terminal domain‐dependent manner. Conclusions Our study revealed a previously uncharacterized mechanism of CCNB1IP1‐mediated MYCN protein stability and will provide new prospects for precise treatment of MYCN‐AM NB based on MYCN‐CCNB1IP1 interaction.

Control Analysis of Protein-Protein Interaction Network Reveals Potential Regulatory Targets for MYCN

Molecular Mechanisms of <i>MYCN</i> Dysregulation in Cancers

Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis

MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products

Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN.

CCNB1IP1 prevents ubiquitination-mediated destabilization of MYCN and potentiates tumourigenesis of <i>MYCN</i>-amplificated neuroblastoma

A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle

P300 Interacted with N-Myc and Regulated Its Protein Stability Via Altering Its Post-Translational Modifications in Neuroblastoma

Identification of MYC synthetic lethal genes and networks

MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and is Activated Through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification.

Identification and analysis of the regulatory network of Myc and microRNAs from high-throughput experimental data

The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma

Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma

Identification of cancer-keeping genes as therapeutic targets by finding network control hubs

CCNB1IP1 stabilizes MYCN through suppression of Fbxw7-mediated degradation and facilitates the growth of MYCN-amplified neuroblastoma

Targeting Mycn Ires in Mycn-Amplified Neuroblastoma with Mir-375 Inhibits Tumor Growth and Sensitizes Tumor Cells to Radiation

The MYCN 5′ UTR as a therapeutic target in neuroblastoma

P300 interacted with N-Myc and regulated its protein stability via altering its posttranslational modifications in neuroblastoma